Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, resulting in vasodilation and reduced systemic vascular resistance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Short-term treatment of hypertension when oral therapy is not feasible or desirable,Management of hypertensive emergencies,Postoperative hypertension
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion: Initial rate 5 mg/hour, titrate by 2.5 mg/hour every 5-15 minutes to a maximum of 15 mg/hour. For hypertension, typical maintenance 3-5 mg/hour.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is 8.6 hours (range 6–10 hours). In patients with hepatic impairment, half-life may be prolonged up to 14 hours. No significant change in renal impairment.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites are excreted renally and fecally. Fecal excretion accounts for approximately 35% of total elimination.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
>95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Vd is approximately 0.4 L/kg in healthy subjects, indicating moderate tissue distribution. Increased Vd in patients with hepatic cirrhosis (up to 1.0 L/kg).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral bioavailability is approximately 35% due to extensive first-pass hepatic metabolism. Intravenous bioavailability is 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific GFR-based dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor closely.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class A: Reduce initial dose to 2.5 mg/hour; titrate cautiously. Class B or C: Avoid use or use very low doses under close monitoring.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Not FDA-approved for pediatric use. Limited data: Continuous infusion 0.5-5 mcg/kg/min, titrate to effect. Initiate at 0.5-1 mcg/kg/min.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients: Initiate at lower infusion rates (e.g., 2.5 mg/hour) and titrate slowly due to increased sensitivity and higher risk of hypotension.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None.
None.
May cause hypotension, especially in patients with compromised cardiac function,Use with caution in patients with hepatic impairment or reduced hepatic blood flow,May exacerbate angina in patients with obstructive coronary artery disease,Monitor blood pressure, heart rate, and ECG continuously during infusion,Risk of peripheral edema, headache, and reflex tachycardia
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Known hypersensitivity to nicardipine or any component of the formulation,Patients with severe aortic stenosis (may reduce coronary perfusion pressure),Patients with advanced aortic stenosis (may precipitate left ventricular failure)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
NO FOOD INTERACTIONS DUE TO INTRAVENOUS ROUTE. HOWEVER, GRAPEFRUIT JUICE MAY INCREASE SYSTEMIC EXPOSURE IF TAKEN ORALLY; IV ADMINISTRATION NOT AFFECTED.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
First trimester: Limited data; no clear evidence of major malformations in humans, but animal studies show fetotoxicity at high doses. Second/third trimester: Potential fetal hypoxia due to maternal hypotension; consider risk-benefit.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Excreted in breast milk in small amounts (M/P ratio unknown); use with caution, monitor infant for hypotension.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Dose may require adjustment due to increased volume of distribution and clearance; start with lower doses and titrate to effect.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
NICARDIPINE IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER WITH HIGH VASCULAR SELECTIVITY. INTRAVENOUS ADMINISTRATION ALLOWS PRECISE TITRATION FOR HYPERTENSIVE URGENCY OR EMERGENCY. IT IS METABOLIZED BY CYP3A4; CAUTION WITH STRONG INHIBITORS/INDUCERS. CONTINUOUS BLOOD PRESSURE MONITORING REQUIRED. MAY CAUSE REFLEX TACHYCARDIA. AVOID IN ADVANCED AORTIC STENOSIS. SOLUTION IS LIGHT-SENSITIVE; PROTECT FROM LIGHT DURING INFUSION. TITRATE TO TARGET BP; ONSET ~5 MIN, DURATION 3-4 HOURS.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously to quickly lower your blood pressure.,Your blood pressure will be monitored continuously during infusion.,Report any symptoms of dizziness, headache, or ankle swelling.,Do not stop the medication abruptly; it is administered by healthcare professionals.,Inform your healthcare provider if you have liver disease or aortic stenosis.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Ximelagatran, a prodrug of the direct thrombin inhibitor melagatran, is primarily metabolized by CYP450 enzymes, particularly CYP2C9 and to a lesser extent CYP3A4. Nicardipine, a dihydropyridine calcium channel blocker, is extensively metabolized by CYP3A4. Coadministration of ximelagatran with nicardipine may result in inhibition of CYP3A4-mediated metabolism of nicardipine, leading to increased nicardipine plasma concentrations, enhanced hypotensive effects, and potentially elevated risk of adverse events such as edema, headache, and dizziness."
"Cinnarizine, a piperazine derivative with antihistaminic and calcium channel-blocking properties, inhibits cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of nicardipine, a dihydropyridine calcium channel blocker. This inhibition leads to reduced clearance and elevated plasma concentrations of nicardipine, potentially resulting in enhanced vasodilation, hypotension, reflex tachycardia, and increased risk of adverse effects such as peripheral edema, dizziness, and headache. Clinically, patients may experience exaggerated hypotensive responses and cardiovascular instability."
"Etoricoxib, a selective COX-2 inhibitor, can inhibit the metabolism of nicardipine, a dihydropyridine calcium channel blocker, via competitive inhibition of CYP3A4. This results in elevated plasma concentrations of nicardipine, potentially leading to enhanced hypotensive effects and an increased risk of adverse events such as dizziness, headache, peripheral edema, and reflex tachycardia. Clinically, this interaction may necessitate dose adjustment and careful monitoring of blood pressure and heart rate."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, resulting in vasodilation and reduced systemic vascular resistance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is: Intravenous infusion: Initial rate 5 mg/hour, titrate by 2.5 mg/hour every 5-15 minutes to a maximum of 15 mg/hour. For hypertension, typical maintenance 3-5 mg/hour.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is classified as Category A/B. First trimester: Limited data; no clear evidence of major malformations in humans, but animal studies show fetotoxicity at high doses. Second/third trimester: Potential fetal hypox. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.